StreetInsider.com News Articles

Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings

Wed, 11 Mar 2026 08:30:00 -0400

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the publication of a new study in JCO Precision Oncology highlighting how advanced features of comprehensive genomic profiling (CGP) expand treatment options for cancer patients in community oncology settings. The study, conducted in collaboration with The Oncology Institute (TOI), reveals that features such as tumor-normal matched sequencing, RNA sequencing, and liquid biopsy reflex identify actionable findings that are missed by more limited standard in-network testing.

While organizations like ASCO® and the NCCN® strongly

Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings

Wed, 11 Mar 2026 08:30:00 -0400

While organizations like ASCO® and the NCCN® strongly

Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings

Wed, 11 Mar 2026 08:30:00 -0400

While organizations like ASCO® and the NCCN® strongly

Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings

Wed, 11 Mar 2026 08:30:00 -0400

While organizations like ASCO® and the NCCN® strongly

Tempus AI Inc (TEM) PT Raised to $95 at H.C. Wainwright

Tue, 10 Mar 2026 07:21:43 -0400

(Updated - March 10, 2026 7:21 AM EDT)

H.C. Wainwright analyst Yi Chen raised the price target on Tempus AI Inc (NASDAQ: TEM) to $95.00 (from $89.00) while maintaining a Buy rating.

The analyst commented: "Last week, Tempus AI announced an expanded, multi-year collaboration with Merck (MRK; not rated) to accelerate the discovery and development of precision medicine biomarkers and support Merck’s oncology and potentially broader therapeutic portfolios. Under the agreement, Merck will use Tempus’ de-identified data along with Tempus’ Lens Platform and Workspaces environment to enable researchers to efficiently conduct complex analyses on training-ready multimodal datasets and generate novel insights to

Tempus AI Inc (TEM) PT Raised to $95 at H.C. Wainwright

Tue, 10 Mar 2026 07:21:43 -0400

(Updated - March 10, 2026 7:21 AM EDT)

H.C. Wainwright analyst Yi Chen raised the price target on Tempus AI Inc (NASDAQ: TEM) to $95.00 (from $89.00) while maintaining a Buy rating.

Form SCHEDULE 13G Tempus AI, Inc. Filed by: ARK Investment Management LLC

Fri, 06 Mar 2026 14:47:00 -0400

si-local-file:///var/storage/secattach/20260306/26124763.html

Form SCHEDULE 13G Tempus AI, Inc. Filed by: ARK Investment Management LLC

Fri, 06 Mar 2026 14:47:00 -0400

si-local-file:///var/storage/secattach/20260306/26124763.html

Form 4 Tempus AI, Inc. For: Mar 02 Filed by: Rogers James William

Wed, 04 Mar 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260304/26111765.html

Form 4 Tempus AI, Inc. For: Mar 02 Filed by: Rogers James William

Wed, 04 Mar 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260304/26111765.html

Form 4 Tempus AI, Inc. For: Mar 02 Filed by: Epstein David R

Wed, 04 Mar 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260304/26111772.html

Form 4 Tempus AI, Inc. For: Mar 02 Filed by: Epstein David R

Wed, 04 Mar 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260304/26111772.html

Tempus expands collaboration with Merck for AI-driven precision medicine

Tue, 03 Mar 2026 08:30:47 -0400

Tempus AI Inc. (NASDAQ: TEM) announced an expanded multi-year collaboration with Merck to accelerate biomarker discovery and development for precision medicine applications in oncology and other therapeutic areas.

Under the agreement, Merck will access Tempus' de-identified multimodal datasets through the company's Lens Platform and Workspaces environment. The platform utilizes GPU infrastructure to enable researchers to conduct analyses on training-ready datasets for therapy development and optimization.

"This collaboration builds on our existing relationship and reflects our shared commitment to harnessing the power of multimodal datasets with AI to deliver better options for patients," said Ryan Fukushima, CEO of Data & Apps at Tempus.

Merck

Tempus expands collaboration with Merck for AI-driven precision medicine

Tue, 03 Mar 2026 08:30:47 -0400

Merck

Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine

Tue, 03 Mar 2026 08:30:00 -0400

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Merck, known as MSD outside of the United States and Canada, today announced an expanded, multi-year collaboration aimed at accelerating the discovery and development of precision medicine biomarkers and supporting Merck’s oncology and potentially broader therapeutic portfolios.

“This collaboration builds on our existing relationship and reflects our shared commitment to harnessing the power of multimodal datasets with AI to deliver better options for patients,” said Ryan Fukushima, CEO, Data & Apps at Tempus. “We’ve spent years configuring our

Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine

Tue, 03 Mar 2026 08:30:00 -0400

Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine

Tue, 03 Mar 2026 08:30:00 -0400

Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine

Tue, 03 Mar 2026 08:30:00 -0400

Tempus AI Inc (TEM) PT Lowered to $70 at Morgan Stanley

Tue, 03 Mar 2026 08:12:45 -0400

Morgan Stanley analyst Kallum Titchmarsh lowered the price target on Tempus AI Inc (NASDAQ: TEM) to $70.00 (from $85.00) while maintaining a Overweight rating.

Form 144 Tempus AI, Inc. Filed by: Rogers James William

Mon, 02 Mar 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260302/26093058.html

Form 144 Tempus AI, Inc. Filed by: Rogers James William

Mon, 02 Mar 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260302/26093058.html

Form 144 Tempus AI, Inc. Filed by: Epstein David R

Mon, 02 Mar 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260302/26093011.html

Form 144 Tempus AI, Inc. Filed by: Epstein David R

Mon, 02 Mar 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260302/26093011.html

Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference

Thu, 26 Feb 2026 08:30:00 -0400

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Morgan Stanley Technology, Media, and Telecom Conference on Tuesday, March 3 in San Francisco. Eric Lefkofsky, Tempus Founder and CEO, will participate in a fireside chat at 9:15 AM PST.

The live webcast may be accessed directly using the following link: https://event.webcasts.com/starthere.jsp?ei=1753938&tp_key=e25fc24c17&tp_special=8. A recording will be made available on the Events page of Tempus’ Investor Relations website.

About Tempus

Tempus is a technology company advancing

Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference

Thu, 26 Feb 2026 08:30:00 -0400

About Tempus

Tempus is a technology company advancing